Director share purchases

LungLife AI, Inc.
(the “Company” or “LungLife”) 

Director share purchases

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors.

On 14 August 2023, Paul Pagano, Chief Executive Officer, purchased 7,123 Common Shares at a price of 69.84 pence per share. Following this purchase, Paul Pagano now holds 12,123 Common Shares, representing approximately 0.047% of the outstanding share capital of the Company.

In addition, on 14 August 2023, David Anderson, Chief Financial Officer, purchased 7,123 Common Shares at a price of 69.84 pence per share. Following this purchase, David Anderson now holds 12,123 Common Shares, representing approximately 0.047% of the outstanding share capital of the Company.

Click HERE for the full announcement.